Dentsply confirms $1.8bn Astra Tech buy; deal propels firm to No 3 in dental implants
This article was originally published in Clinica
Executive Summary
AstraZeneca is to sell its Astra Tech medical device subsidiary to Dentsply International for around $1.8bn in cash, both parties confirmed today. The deal is expected to "more than double" Dentsply's current position in the dental implants market, the York, Pennsylvania firm says, and will enable it to diversify into other medical device markets.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.